SynthesisBMC cardiovascular disorders2026
Bone marrow-derived stem cells for acute myocardial infarction: a systematic review and meta-analysis on efficacy and safety.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute myocardial infarction (AMI) is one of the main causes of global morbidity and mortality. Stem cell-based therapy offers a promising approach for myocardial regeneration and tissue repair. Among them, bone marrow-derived stem cells (BMSCs) have shown remarkable therapeutic benefits in various clinical scenarios. Therefore, this study aimed to systematically evaluate the efficacy and safety of BMSCs in patients with AMI.
methodsThe computer retrieved the Cochrane Library, PubMed, Web of Science and Wiley Online Library databases, collected the randomized controlled trials on BMSCs for the treatment of AMI published in October 2025, and conducted data analysis using RevMan 5.4 and Stata 18.0.
resultsWe enrolled 25 trials with 1822 patients, 960 patients in the BMSCs group, and 862 patients in the conventional treatment group. Meta-analysis findings indicated that BMSCs transplantation significantly enhanced left ventricular ejection fraction (LVEF) of patients with AMI relative to controls (MD = 2.45, 95% CI: 1.39 to 3.51) and reduced wall motion score index (WMSI) (SMD = -0.32, 95% CI: -0.49 to -0.15). For left ventricular end-diastolic volume (LVEDV) (SMD = -0.01, 95% CI: -0.16 to 0.13), left ventricular end-systolic volume (LVESV) (SMD = -0.04, 95% CI: -0.13 to 0.06) and myocardial infarct size (SMD = 0.01, 95% CI: -0.14 to 0.15), there was a trend toward improvement after infusion of BMSCs, but the difference was not statistically significant. In terms of safety, BMSCs transplantation did not increase the risk of major adverse cardiovascular events (MACEs) (OR = 0.80, 95% CI: 0.57 to 1.12).
conclusionBMSCs can effectively improve cardiac function in patients with AMI and demonstrate a favorable safety profile. However, their effect on ventricular remodeling remains uncertain, warranting further high-quality evidence to assess long-term outcomes.
trial registrationCRD420251147871.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.